AI-Discovered Drug Reverses Aging Markers in Study, Biotech Says

Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). First Universal Consensus Across Six Independently-Developed Proteomic Aging Clocks: Analyzing 12-week longitudinal Olink proteomic data from 42 IPF patients, …

AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says

An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.

NewLimit Says Its AI System Reversed Aging Signs in Human Liver Cells

NewLimit, the longevity biotech backed by Coinbase CEO Brian Armstrong, says its AI system Ambrosia reprogrammed old human liver cells to behave like young ones again. Investors just backed the claim with a $435 million Series C that pushed the company's valuation to $3.1 billion, even though the data hasn't been peer reviewed and human trials don't start until 2027.

Insilico Medicine's rentosertib shows potential to slow aging in landmark Phase III trial

Insilico Medicine's AI-discovered drug rentosertib enters Phase III trials for lung fibrosis, targeting cellular senescence with implications for

Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial

Rentosertib's success could revolutionize aging treatment, influencing therapies for numerous age-related diseases beyond lung conditions. The post Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial appeared first on Crypto Briefing .